Spanberger Announces Support for Bipartisan Bill to Increase Competition in the Pharmaceutical Marketplace, Lower Prescription Drug Costs

Apr 29, 2019
Healthcare
Press

The CREATES Act Would Stop Pharmaceutical Companies from Engaging in Practices that Block the Availability of Lower-Cost Generic Drugs

WASHINGTON, D.C. — U.S. Representative Abigail Spanberger today announced her support for a bipartisan bill that would make it easier for Central Virginians to access lower-cost generic prescription drugs.

Spanberger is now a cosponsor of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, which would prohibit pharmaceutical companies from participating in certain anti-competitive practices that block cheaper generic drugs from entering that market. The bipartisan bill would increase competitive options for prescription drugs by cracking down on pharmaceutical companies’ ability to delay access to generic versions of expensive brand-name drugs.

Earlier this month, Spanberger introduced and led a bipartisan bill to hold third-party intermediaries accountable and help address the root causes of the prescription drug affordability crisis. Her legislation passed unanimously out of the House Ways and Means Committee.

“Skyrocketing prescription drug prices force far too many Central Virginians to make difficult financial decisions as they look to live a healthy life. To help provide relief, we need to do more to foster healthy competition—and we must address the predatory practices of certain companies that knowingly block access to cheaper medication for senior citizens, working families, and children,” said Spanberger. “Our bipartisan bill would create more competition, lower drug costs, and provide a significant savings to taxpayers and insurers. I’m proud to support this legislation—and as we continue to find new ways to address this crisis, I’ll continue fighting to address the prescription drug crisis as a moral issue, not a partisan game.”

The nonpartisan Congressional Budget Office has estimated that the CREATES Act would result in a $3.9 billion net decrease in the federal deficit.

Specifically, the CREATES Act would allow generic manufacturers facing delay tactics to bring action in federal court to obtain the samples they need—and  courts would be authorized to award monetary damages sufficient to deter future gaming of the healthcare system. Additionally, the bill addresses another anti-competitive practice in which brand-name drug companies may prevent generics and biosimilars from participating in the process to develop a Food and Drug Administration (FDA)-approved shared safety protocol. The CREATES Act would allow the FDA to approve alternative safety protocols that meet the same rigorous standards.

The CREATES Act is endorsed by the Association for Accessible Medicines, the American College of Physicians, the American Hospital Association, the Campaign for Sustainable Rx Pricing, and America’s Health Insurance Plans. The legislation is also supported by consumer groups including AARP, the Consumers Union, and Public Citizen.

The CREATES Act is led by U.S. Representatives David Cicilline (D-RI), Jim Sensenbrenner (R-WI), Jerrold Nadler (D-NY), Doug Collins (R-GA), Peter Welch (D-VT), and David McKinley (R-WV).

Background

Since arriving in the U.S. House, Spanberger has been fighting to address the prescription drug affordability crisis in Central Virginia. In January, she helped introduce the Medicare Negotiation and Competitive Licensing Act, which would authorize the U.S. Department of Health and Human Services to negotiate directly with pharmaceutical providers within Medicare Part D to help lower costs.

Last month, Spanberger helped introduce and pass landmark campaign finance and ethics reform legislation that would strengthen transparency in the U.S. political system and limit the influence of special interests—including pharmaceutical companies. During a press conference prior to the passage of the legislation, she shared the story of Central Virginians concerned about rising prescription drug prices—and she stressed why increased transparency would restore faith in the democratic process and the ability of Members of Congress to affect change on these issues. Click here to watch the full press conference.

###

Recent Posts


Feb 29, 2024
Economy & Jobs

Spanberger Statement on Vote to Prevent Government Shutdown, Protect Virginia’s Economy

WASHINGTON, D.C. — U.S. Representative Abigail Spanberger today released the following statement after voting with a bipartisan majority of the U.S. House to pass a short-term, stopgap funding measure — known as a “continuing resolution” — to avoid a shutdown that would damage Virginia’s economy. The legislation includes two staggered deadlines to keep the federal […]



Feb 29, 2024
Press

During Black History Month, Spanberger Introduces Bill to Name Fredericksburg Post Office for Civil Rights Leader, Gladys P. Todd

Gladys P. Todd Was A Revered School Teacher, Voting Rights Advocate, & Community Organizer in Fredericksburg WASHINGTON, D.C. — U.S. Representative Abigail Spanberger today introduced legislation to rename a Fredericksburg post office after Gladys P. Todd, a prominent leader in the Fredericksburg civil rights movement. Located at 1285 Emancipation Highway in Fredericksburg, the post office […]



Feb 28, 2024
Infrastructure

Spanberger Leads Virginia Lawmakers in Working to Protect $30 Internet Discount for Virginia Families, Fund Affordable Connectivity Program

The “Affordable Connectivity Program” Right Now Helps More than 455,000 Virginia Households Afford High-Speed Internet WASHINGTON, D.C. — U.S. Representative Abigail Spanberger today led members of the Virginia congressional delegation in a bipartisan effort urging the U.S. House Committee on Appropriations to extend funding for a key discount program that allows more Virginia families to […]